BioCentury
ARTICLE | Clinical News

Replagal agalsidase alfa enzyme replacement therapy regulatory update

April 2, 2001 7:00 AM UTC

The EU's CPMP recommended approval of Replagal to treat Fabry disease. The product also is under review in the U.S. and the FDA has requested additional data (see BioCentury, Jan. 8). ...